Bausch & Lomb Corp
BLCO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$39.00 | Nsczsc | Hptdwqrxh |
Bausch & Lomb Earnings: Solid Quarter on Broad-Based Growth but Cutting FVE After Updating Drivers
Narrow-moat Bausch & Lomb reported first-quarter earnings that came largely in line our expectations. Total sales of $1.0 billion were up 18% year over year from strong demand in consumer products and a substantial sales hike in the ophthalmic pharmaceuticals segment thanks to Xiidra and Miebo contributions. Despite unfavorable foreign exchange, which created about $20 million in headwinds, strong execution across categories made for a solid quarter.